Osaka, Japan, Aug 3, 2006 - (JCN Newswire) - Takeda Pharmaceutical Company Limited today announced that on July 31, 2006, Takeda Global Research & Development Centre (Europe), Ltd. (“TGRD Europe”) was granted a marketing authorisation for Competact(TM), a fixed combination tablet of ACTOS(R)(pioglitazone HCl) 15mg and metformin HCl 850mg from the European Commission. TGRD Europe submitted that application on February 28, 2005, and received a positive opinion on June 2, 2006 from The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMEA”).
